Percentage of life sciences firms that expect benefits from U.S. tax reforms 2018

Published by
Matej Mikulic,
Dec 19, 2022
This statistic depicts the percentage of biopharma and medtech firms that expect to benefit from U.S. tax reforms, according to a survey conducted during summer 2018. According to the survey, 30 percent of companies expect to see benefits within the next fiscal year.

Percentage of biopharma and medtech companies that expect to benefit from U.S. tax reforms as of 2018

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

October 2018

Region

Worldwide, United States

Survey time period

summer 2018

Number of respondents

60 executives

Special properties

30 from biopharma, 30 from medtech companies

Supplementary notes

Original question: "Do you expect your company to realize benefits from U.S. tax reform? If so, when you expect your company to realize these benefits?"

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Coronavirus: the pharma and medtech response "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Biotechnology industry in Germany Global pharmaceutical industryMedical technologyTop pharmaceutical drugsPharma e-commerce
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.